CinRx has teamed up with Sam Waksal’s Graviton Bioscience to develop a ROCK2 program for pulmonary arterial hypertension and other cardiovascular conditions. The collaboration follows Graviton’s prior work on ROCK2 that produced Rezurock, underscoring the target’s continued pull for drug development teams. The partnership centers on building a pipeline around ROCK2 biology with an eye toward translating the mechanism into new cardiovascular indications beyond CinRx’s initial focus area. For investors and industry watchers, the move signals continued confidence in kinase-adjacent pathway strategies in cardiopulmonary disease. While specific clinical stage details were limited in the provided brief, the key development for the sector is the alliance combining CinRx’s development execution with Graviton’s ROCK2 track record.